Novartis AG (VTX:NOVN) has been given a CHF 90 price objective by stock analysts at HSBC Holdings plc in a report released on Thursday. The firm currently has a “buy” rating on the stock.

Several other research firms also recently weighed in on NOVN. Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a report on Tuesday, August 8th. J P Morgan Chase & Co set a CHF 70 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th. Kepler Capital Markets set a CHF 87 price target on shares of Novartis AG and gave the stock a “buy” rating in a research report on Monday, August 28th. Jefferies Group LLC set a CHF 100 price objective on Novartis AG and gave the stock a “buy” rating in a report on Monday, May 29th. Finally, UBS AG set a CHF 78 price objective on Novartis AG and gave the stock a “neutral” rating in a report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. Novartis AG has an average rating of “Hold” and a consensus target price of CHF 85.

Shares of Novartis AG (VTX:NOVN) opened at 80.15 on Thursday. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 84.35. The firm has a market cap of CHK 187.78 billion and a PE ratio of 29.26. The company’s 50-day moving average is CHK 80.92 and its 200-day moving average is CHK 78.33.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/07/novartis-ag-novn-pt-set-at-chf-90-by-hsbc-holdings-plc.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.